Neil Butt

Chief Executive Officer of Orbit Discovery a functional screening service company focused on the use of novel bead and microfluidic technology platforms to improve the throughput of functional screening, when searching for agonist of antagonists. The Orbit technologies encompass target protein expression and purification, with a focus on GPCRs; affinity screening to identify panels of target binding therapeutic candidates; and functional screening in cell-based assays. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics for our Partners and collaborators, these parties encompass large scale pharmaceutical companies and biotechnology companies. The company is based in the Oxford Science Park and benefits from the expertise and experience of its founders, Professor Graham Ogg (University of Oxford) and Professor Terry Rabbits (the Institute of Cancer Research). For more information, please visit https://www.orbitdiscovery.com/

Head of business development and corporate development activities for IONTAS, a antibody discovery and licensing company. IONTAS have developed and are offering mammalian display and phage display services and also technology licensing opportunities for both bespoke phage display libraries and mammalian display. IONTAS was also acquired by FairJourney Biologics (FJB) in May 2020 to become, one company with two brands, where IONTAS focus on technology and FJB on services. Licenced mammalian display platform on a non-exclusive basis to BMS, allowing BMS to apply the technology to their antibody discovery programs.

Head of business development activities for Abzena and part of the executive management team. After the acquisition of Antitope by Polytherics, the joint group became Abzena. The company focused on the development of better biopharmaceuticals by the assessment and removal immunogenicity from therapeutic proteins and peptides and in the development of ADCs using the novel ThioBridge conjugation technology. During the three year tenure, the company listed on London Stock Exchange AIM market, raising £20 Million and acquired two US companies to extend services through to GMP manufacturing for antibodies and ADC's

Led all business development and corporate activities for Antitope and established the company as a brand leader in the assessment and removal of immunogenicity from therapeutic antibodies and proteins. Member of the company Executive Management team which oversaw year on year double digit growth and the eventual acquisition by Polytherics in 2013.

Primary roles included development of commercial opportunities for novel technologies within the healthcare industry, R&D management; product development within the healthcare industry; and interim management in small and start up companies (primarily business develpment and programme management functions). Key interim roles included: IMI Norgren - Buisness Develpment - Worked with senior management to develop a business development group focused on the healthcare industry. Oversaw the selling functions on several novel technologies now in market. Enigma Diagnostics - Interim Programme Director - Interim role whist at PA Consulting Group. Primary role was to re-organise the R&D functions and prioritise all R&D functions. Significant commercial functions in assisting deal negotiations also became part of the role.Successfully restructured R&D to focus on commercial aims of the business groups. ITI Scotland - Interim Program Director - Interim role whilst at PA Consulting Group. Coordinated academic and commercial groups to develop complex diagnostic and theranostic platform. Primary aim was to develop commercially viable IP for exploitation by commercial partners. Other functions included: Due diligence for pharmaceutical technology and company acquisitions Strategy development for pharmaceutical and healthcare companies

Initially R&D Manager for UK Biosciences Group developing new technologies for DNA purification. Collaborated closely with US and other UK research groups to develop technologies associated with both diagnostics and pharmaceutical industries. Switched to marketing and business development group in 1998 and focused on new technologies and novel applications for new technologies.

Head of Research and Development for a start up company (CMT) developing novel technologies for DNA purification and analysis. Took over R&D management from founder within 12 months of joining company and developed technologies which changed the company strategy. Set up a small service based group within the company to drive revenues and increase turnover. Involved in technical and commercial discussions prior to acquistion by Whatman.